The clean safety profile supports advancing nintedanib DPI into Phase 2, reducing clinical risk for this asset. Monitor Phase 2 enrollment updates and future efficacy readouts (FVC decline) as key catalysts. The conference call at 4:30 p.m. ET today may provide additional detail on development timelines.
Drug in focus
MNKD drug pipeline →nintedanib DPI
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2 (enrolling)
- Time to market
- At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
- Next catalyst
- None dated
What to watchWatch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $3.85entry
- T+1 · 4mo ago +6.75%α +5.08% · $4.11
- T+5 · 3mo ago +6.49%α +0.96% · $4.10
- T+20 · 3mo ago +6.23%α +1.21% · $4.09
- T+60 · 26d ago −16.88%α −21.61% · $3.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint with no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations, while cough events were mild and transient. The global Phase 2 INFLO-2 trial is now actively enrolling, supporting continued pipeline development in a large unmet need market.
Key Facts
- Phase 1b INFLO-1 met primary safety/tolerability endpoint in 27 IPF patients across 10 U.S. sites
- No serious adverse events, no drug-related GI side effects, no bronchospasm, no discontinuations or dose reductions
- Cough was predominantly mild/transient with no cough-related discontinuations; ~450 inhalations administered in IPF patients
- Global Phase 2 INFLO-2 actively enrolling ~210 patients across ~85 sites worldwide
- MannKind has two FDA-approved DPI products using the Technosphere platform, supporting formulation expertise
Financial Impact
Positive Phase 1b data de-risks MNKD-201 pipeline; Phase 2 enrollment underway; no financial figures disclosed
Risk Factors
- Phase 2 may not replicate safety profile or demonstrate efficacy on FVC endpoints
- Competition from oral nintedanib (Ofev) and other IPF therapies may limit commercial potential
- Regulatory pathway for inhaled nintedanib remains uncertain until larger trials complete
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335054 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Viewing Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers